A systematic review and meta-analysis of weight loss in control group participants of lifestyle randomized trials

Amira Bouzalmate Hajjaj1, Paloma Massó Guijarro2,4, Khalid Saeed Khan1,3, Aurora Bueno-Cavanillas1,3,4 & Naomi Cano-Ibáñez1,3,4

Randomized clinical trials (RCTs) of lifestyle modification have reported beneficial effects of interventions, compared to control. Whether participation in the control group has benefits is unknown. To determine whether control group participants experience weight loss during the course of RCTs. After prospective registration (PROSPERO CRD42021233070), we conducted searches in Medline, Scopus, Web of Science, Cochrane library and Clinicaltrials.gov databases from inception to May 2021 without language restriction to capture RCTs on dietary advice or physical activity interventions in adults with overweight, obesity or metabolic syndrome. Data extraction and study quality assessment was performed by two independent reviewers. Weight loss in the control group, i.e., the difference between baseline and post-intervention, was pooled using random effects model generating mean difference and 95% confidence interval (CI). Heterogeneity was assessed using the I² statistical test. Subgroup meta-analysis was performed stratifying by follow-up period, type of control group protocols and high-quality studies. Among the 22 included studies (4032 participants), the risk of bias was low in 9 (40%) studies. Overall, the controls groups experienced weight loss of –0.41 kg (95% CI –0.53 to –0.28; I² = 73.5% p < 0.001). To identify a result that is an outlier, we inspected the forest plot for spread of the point estimates and the confidence intervals. The magnitude of the benefit was related to the duration of follow-up (–0.51 kg, 95% CI –0.68, –0.3, for 1–4 months follow-up; –0.32 kg, 95% CI –0.58, –0.07, 5–12 months; –0.20 kg, 95% CI –0.49, 0.10, ≥12 months). In high-quality studies we found an overall weight loss mean difference of –0.16 (95% CI –0.39, 0.09) with a considerable heterogeneity (I² = 74%; p < 0.000). Among studies including control group in waiting lists and combining standard care, advice and material, no heterogeneity was found (I² = 0%, p = 0.589) and (I² = 0%, p = 0.438); and the mean difference was –0.84 kg (95% CI –2.47, 0.80) and –0.65 kg (95% CI –1.03, –0.27) respectively. Participation in control groups of RCTs of lifestyle interventions had a benefit in terms of weight loss in meta-analysis with heterogeneity. These results should be used to interpret the benefits observed with respect to intervention effect in trials. That control groups accrue benefits should be included in patient information sheets to encourage participation in future trials among patients with overweight and obesity.

Abbreviations
RCTs  Randomized controlled trials  
BMI  Body Mass Index

Obesity, a major cause of morbidity and mortality worldwide with over 650 million affected adults1–2, has attracted interest in preventive research of various study designs in light of its impact on the healthcare system and the economy3–4. However, it is challenging to encourage patients to take part in randomized trials, in part because
of the perception that participation in control group may not be valuable\(^5\). With a median dropout rate of 24%, difficulties in recruiting, retaining and obtaining outcome data from participants are common in lifestyle randomised controlled trials (RCTs)\(^6–8\) and they contribute to trials being underpowered or invalid. There is a need to generate information about benefits of participation in trials to entice participants to engage in obesity research in a manner that robust and timely results can be produced to inform future practice and policy\(^9\).

A literature search demonstrated that participants of RCTs, on average, experienced better outcomes compared with those outside trials\(^10–19\). There is a scarcity of reviews concerning participation in lifestyle modification research\(^19\), and none is focused in overweight or obese participants being at risk of a chronic disease to assess benefits of clinical trials based in diet in the last decade. Descriptions of treatment and outcomes of control groups participants have received limited attention\(^17,18\). In obesity research it would be important to know if control groups experience any benefits inside RCTs, not only to encourage participation, but also to interpret findings of trials on effect of participation, with respect to intragroup differences in control and intervention groups. In this systematic review and meta-analysis, we aimed to determine whether participants with overweight, obesity or metabolic syndrome, allocated to control groups in lifestyle modification research experienced benefits in terms of weight loss during the course of the RCTs.

**Material and methods**

We performed the systematic review after prospective registration (PROSPERO number: CRD42021233070) and reported it in accordance with relevant guidelines\(^19\).

**Search and selection.** We conducted a comprehensive literature search without language restrictions in electronic databases (Medline via ProQuest, Scopus, Web of Science, Cochrane library and Clinicaltrials.gov) from inception to May 2021. In addition, we hand-searched reference lists of previous reviews and included articles. The search term combination was based on MeSH terms, free-text words and word variants. The inclusion criteria lifestyle intervention RCTs based on diet, with or without physical activity, and with or without behavioural support, among adults with overweight, obesity or metabolic syndrome. In crossover RCTs, control group participants were on a waiting list with standard care to receive further intervention after a wash-up period. The combination of keywords and terms included: metabolic syndrome, obesity, overweight, diet, hypocaloric diet, Mediterranean diet, physical activity, educational intervention, preventive program, diabetes mellitus, cancer, cardiovascular disease, weight loss, mortality, randomized controlled trial, lifestyle intervention, lifestyle modification, lifestyle risk reduction (Appendix 1). All citations found were exported to Endnote where duplicates were removed.

Two reviewers (ABH and PMG) carried out a search strategy independently using electronic databases and manual searches. Both of them screened all abstracts and titles. Exclusion criteria were studies conducted on children, adolescents and pregnant women; participants with established cardiovascular disease, cancer, diabetes or eating disorders; sample selection based on special conditions like familiar hypercholesterolemia or bariatric surgery, polycystic ovary syndrome, kidney disease or chronic obstructive pulmonary disease. We also excluded studies with no control group or those which did not provide outcome data for the control group. Study designs other than RCT and types of interventions other than lifestyle modification (like drug treatments or diet supplements) were excluded. Any disagreement regarding the articles' inclusion was resolved by taking the opinion of a third researcher (NCI). We contacted authors to achieve not available full text articles. Finally, the selection of articles was based on independent review of full texts to ensure the inclusion and exclusion criteria have been fulfilled.

**Data extraction and risk of bias.** The key characteristics of selected studies were extracted independently by both reviewers (ABH and PMG) after reading the full text. We used a predefined form for data extraction and, when necessary, we contacted directly the authors through ResearchGate for relevant data that were not provided in the manuscripts. Jadad scale (score range 0–5)\(^20\) was used to assess the methodological quality of randomization, blinding and patient withdrawals or dropouts. RCTs with a score of ≥3 was considered to be of high quality. We used this scale because the features assessed apply to control group, and also it has allowed us to verify the overall quality of the trials included. Given the type of lifestyle interventions used in these RCTs, double-blind was not possible. Disagreement was resolved by discussion between both reviewers or consultation with the third reviewer.

**Data synthesis and statistical analysis.** We used the outcomes of the control groups reported by the authors as the mean difference in kg of body weight lost from baseline to post-participation and its standard deviations (SD). In three reviews\(^21–23\), which is the 13.6% of the studies, did not provide explicitly the mean difference. We calculated the weight change from the mean values reported by the authors for control group at basal and post-participation time in the RCT. We calculated the standard deviation (SD) using the confidence interval (CI) with this formula: $SD = \sqrt{n}$. Meta-analysis was deployed to comply with the recommended statistical approach, ensuring that the same metric unity (kg) was used to estimate mean difference and that the effect of the advice to control group was comparable across trials\(^24\), constructing forest plots with Stata v.15 software (Stata Corp., 2015, College Station, TX, USA). A random effects model was performed since each study provides information about a different effect size. We attempted to ensure that all these effect sizes are represented in the summary, and did not remove a small study by giving it a very small weight, as it would be done in a fixed-effect analysis. Heterogeneity among studies was assessed using Q test and I-squared ($I^2$) statistics. We assumed that an $I^2 > 50\%$ indicates substantial heterogeneity and $I^2 > 75\%$ considerable heterogeneity\(^25,26\). In order to find out whether control group counselling was sufficiently similar across trials, we followed the criteria established by
the Cochrane Handbook for Systematic Reviews of Interventions. Subgroup meta-analysis was performed stratifying by follow-up period, type of control group protocols, and high-quality studies.

Results

Study selection and quality assessment. A total of 846 records were identified initially. In total, 22 studies with 4032 participants were finally included (Fig. 1). The main characteristics of the studies included are summarized in Table 1. In all RCTs a lifestyle intervention was performed. The studies were conducted in several countries United Kingdom (3), United States (3), Spain (3), Japan (2), Australia (2), China (1), South Korea (1), Netherlands (1), Denmark (1), Thailand (1), Finland (1), Germany (1), Italy (1) and Saudi Arabia (1). In total, only 2 studies were published before 2010. Of the total, 9 studies (40%) were considered of high quality and 13 studies (60%) were classified as low quality (Fig. 2). Cohen’s Kappa coefficient (κ) was 0.80 indicating a high inter-rater reliability between the two reviewers concerning study quality assessment.

Characteristics of control groups. In our selected studies the sample size ranged from 32 to 626 participants, aged between 18 and 70 years old (mean age 53.92 years). Each study applied different inclusion criteria concerning the BMI. The mean of BMI was 31.93 kg/m² in control group at baseline, ranging from 25.6 kg/m² to 39.8 kg/m². Four studies included only women whereas three studies enrolled only men. One article set obstructive sleep apnoea hypopnoea syndrome as other inclusion criteria, while another study included prediabetic patients that have overweight or obesity. In one of our studies having overweight or obesity was not an inclusion criterion, but all participants had overweight with a BMI > 30.2 in the intervention and > 29.9 in the control group, that why we decided to include it in the review.

In six studies control group received only standard care, while in three studies they were given extra nutritional advice. In nine studies they received extra material, like written information, educational booklets or leaflets. Finally, in four studies control group participants were waitlisted to receive the programme after data extraction. The length of the follow-up ranged from 1 to 24 months. We considered as time points the end-point of the intervention provided by the authors. If these data were not available, post-intervention follow-up value was considered, like in one study where outcomes were measured at 6 months, although the follow-up lasted up to 12 months. The same criterion was applied to another study, where the effects of only the first three months of intervention were reported, whilst the intervention lasted up to 12 months. In two studies the intervention was carried out during 12 months and, afterwards, the participants were followed up for other 12 months (post-intervention). Finally, in a RCT the intervention lasted 3 months, although the
| References | Country | Population randomized (N) and follow-up period | Patients’ characteristics | Type of intervention | Length and duration of interventions | Type of care protocols in CG | Personnel conducting intervention | Weight loss in CG Mean difference (SD) and 95% CI |
|-----------|---------|-----------------------------------------------|--------------------------|----------------------|--------------------------------------|-------------------------------|---------------------------------|-----------------------------------------------|
| Greaves39  | UK      | N = 108 12 months                             | Age: 40–74 BMI ≥ 28; High CV risk | LWO: Not specified | DA: Caloric and fat restriction | Standard care | Pack of written information on CV risk | Nurse and coaches | − 2.04 (6.87) CI (−3.96; 0.12) |
| Lin40      | USA     | N = 124 Outcomes at 6 months follow up until 12 months | Age ≥ 21 BMI ≥ 27 | LWO: Not specified | DA: Reduce fat and sugar intake. Portion control | Standard care | Initial clinical assessment, personalized weight control plan and PA recommendations. Additional educational material at 6 and 12 months | Dietitian and physican | − 0.2 (3.16) CI (−1.4; 1.0) |
| Weinhold43 | USA     | N = 78 3 months                               | Age: 18–65 BMI= 25.0 to 50.0 Prediabetes | LWO: 7% reduction | DA: Caloric and fat restriction | Standard care | Booklet with strategies for self-regulated weight loss | Dietitians | − 0.4 (0.6) CI (−0.59; −0.21) |
| Oh22       | South Korea | N = 32 1 month                            | Age > 20 Rural women with MetS | LWO: Not specified | DA: Caloric and saturated fat restriction | Standard care | Educational booklet | Nurses | − 2 (10.90) CI (−8.59; 4.59) |
| Alghamdi41 | Saudi Arabia | N = 70 3 months                         | Age > 20 BMI ≥ 30 | LWO: ≥ 5% reduction | DA: Caloric and CH restriction | Standard care | Printed health education materials regarding diet and PA | Nurses | − 2.8 (4.96) CI (−3.96; −1.64) |
| Blackford44 | Australia | N = 401 6 months                           | Age: 50–69 Rural adults with, or at risk of MetS | LWO: Not specified | DA: Diet intervention with motivational support | Waitlisted to receive the programme after post-test data collection | Home-based | 1.1 (21.95) CI (−2.29; 4.49) |
| Fernández-Ruiz25 | Spain | N = 74 12 months of intervention, and 1-year follow-up post-intervention | Age: not defined BMI = 25.0–29.9 or BMI > 30 | LWO: Not specified | DA: Modification of unhealthy dietary habits | Standard care | Physicians, nurses, nutritionists and psychologists | | − 0.2 (12.35) CI (−4.18; 3.78) |
| References | Country | Population randomized (N) and follow-up period | Patients’ characteristics | Type of intervention | Lost weight objective | Diet advice | Physical activity advice | Type of intervention Length and duration of interventions | Type of care protocols in CG | Personnel conducting intervention | Weight loss in CG Mean difference (SD) and 95% CI |
|------------|---------|-----------------------------------------------|--------------------------|----------------------|----------------------|-------------|------------------------|--------------------------------------------------------|-----------------------------|--------------------------------|----------------------------------|
| Bo36 Italy N = 335 1 year | Age: 45–64 Adults with MetS | LWO: Not specified | DA: Individually prescribed diet | PAA: To increase 150'/week | TOI: Individual and group-based | L-DI: 5 sessions of 60': 1 individual session and 4 grouped | Standard care | Family physicians and dietitian | 1.63 (6.17) CI (0.83; 2.42) |
| Duijzer34 Netherlands N = 316 18 months | Age: 40–70 High risk of type 2 diabetes | LWO: < 5–10% | DA: Tailored dietary advice | PAA: To increase at least 30'/day, 5 days/week | TOI: Individual and group-based | L-DI: 5 to 8 individual consultations and one group session | Standard care | General practitioners, practice nurses, dieticians and physiotherapists, sport coaches | − 0.4 (3.7) CI (− 1.06; 0.26) |
| Christensen29 Denmark N = 144 12 months (results of the first 3 months) | Age: 18–40 (BMI > 25 or body fat % > 33) | Age: > 40 years (Body fat % > 34) | Female health care workers | LWO: Not specified | DA: Caloric restriction | PAA: To increase | TOI: Individual and group-based | L-DI: 180'/week | Standard care Monthly two-hour oral lecture | 0.68 (2.37) CI (− 0.02; 1.38) |
| Kandula42 USA N = 63 6 months | Age: not defined Participants with at least one atherosclerotic CV risk factor, including obesity | LWO: Not specified | DA: Fat and salt restriction | PAA: To increase 150'/week of moderate intensity | TOI: Group-based classes and individual follow-up telephone support calls | L-DI: weekly group classes (60–90') and individual telephone support during 4 months | Standard care Translated print education materials about atherosclerotic CV risk and healthy behaviours | Dieticians | − 0.2 (3.13) CI (− 1.14; 0.78) |
| Thiabpho30 Thailand N = 60 4 months | Age: 30–50 (BMI)=27.5 | With no non-communicable disease | LWO: Not specified | DA: Caloric restriction and balanced diet | PAA: To increase a minimum of 150'/week of moderate exercise | TOI: Group-based classes and individual telephone support during 4 months | Standard care | Nurses | − 0.7(1.4) CI (− 1.20; − 0.20) |
| Cai38 China N = 480 24 months | Age ≥ 60 BMI ≥ 28 | LWO: Not specified | DA: Caloric, fat and sugar restriction | PAA: To increase 150'/week of moderate exercise | TOI: Group-based and individual based interventions | L-DI: Group-based sessions (120’/week the first 12 months; 120’ monthly the following months) | Standard care 2-h education sessions every 2 months | Dietitians | − 0.03 (2.51) CI (− 0.37; 0.31) |
| Nanri28 Japan N = 107 6 months | Age: not defined Men diagnosed with MetS | LWO: Not specified | DA: Dietary change behaviours | PAA: To increase | TOI: Individual L-DI: Session at baseline and at 3 months | L-DI: Weekly group classes (90–120’) once a week for the first eight weeks and then every two weeks until the 16th week | Standard care | Leaflet at the baseline Nurses | − 0.3 (7.81) CI (− 2.4; 1.8) |

Continued
| References  | Country   | Population randomized (N) and follow-up period | Patients’ characteristics | Type of intervention Length and duration of interventions | Type of care protocols in CG | Personnel conducting intervention | Weight loss in CG Mean difference (SD) and 95% CI |
|-------------|-----------|-----------------------------------------------|---------------------------|----------------------------------------------------------|-----------------------------|----------------------------------|------------------------------------------|
| Maruyama31  | Japan     | N = 111 4 months                              | Age: 30–59 Male office workers with MetS risk factors | LWO: Not specified DA: PAA: To increase TOI: Individual and group-based L-DI: Individual-ized assessment and collaborative goal setting (20‘ and 10’ respectively) plus 2 individual counselling sessions and monthly website advice during the 4-month period | Standard care Registered dietitian and physical trainer | − 0.80 (2.2) CI (−1.50; −0.10) |
| Share26     | Australia | N = 43 3 months                               | Age: 18–30 Women with abdominal obesity [waist circumference (WC) ≥ 80 cm], and who were physically inactive | LWO: Not specified DA: Dietary change behaviours without caloric restriction PAA: To increase 2 session/week TOI: Group-based L-DI: Weekly nutrition education and group cognitive behavioural therapy (60’) | Waitlisted to receive the programme after post-test data collection Qualified exercise scientist, dietitian and counsellor | − 3.60 (18.67) CI (−13.20;6) |
| Moss21      | UK        | N = 60 Intervention 12 weeks (3 months) and follow-up until week 26. (6,5 months) | Age: 18–85 Obese patients (BMI >30) with at least moderate OSAHS | LWO: Not specified DA: Advice based on the principles of the eat well plate PAA: To increase supervised exercise sessions TOI: Group-based L-DI: 3 sessions/week, then 2/week during weeks 5 to 8 and then to 1/week during weeks 9 to 12 | Standard care Basic written lifestyle advice, and a weight loss leaflet Exercise physiologist | 0.2 (21) CI (−8.11; 8.51) |
| Puhkala32   | Finland   | N = 113 12 months of counselling + 12 months of follow up | Age: 30–62 Male truck or bus driver, waist circumference ≥ 100 cm, absence of diabetes and little PA | LWO: < 10% reduction DA: Advice based on the principles of the eat well plate PAA: To increase 30%of moderate-intensity walking TOI: Individual L-DI: during 12 months: 6 individual sessions of 60’ and 7 telephone contacts of 30’ | Standard care Advice and telephone contacts Nutritionists and physiotherapist | − 2.5 (5.9) CI (−4.02; −0.98) |
| Anderson37  | UK        | N = 560 12 months                              | Age: 50–70 Women with excess body weight BMI >25 | LWO: <7% reduction DA: Personalised diet advice PAA: To increase TOI: Individual L-DI: During 12 months 2 individual sessions (60’ and 45’) in the first 3 months and then 9 (15’) support calls over the following 9 months | Standard care Nurses | − 1.2 (5.0) CI (−1.8; −0.6) |

Continued
follow-up was extended to 6.5 months. The lifestyle interventions were carried out by dietitians or nutritionists in three studies14,34,47, and in collaboration with other health professionals (e.g., nurses, physicians, psychologists, sport coaches or trainers) in the rest of the studies. All of the RCT included physical activity (n = 22) as part of the intervention. Control groups received the standard or usual care, or were wait-listed to receive the lifestyle program after data collection in the RCT.

**Data synthesis.** The results of the meta-analysis showed an overall weight loss control group mean difference of −0.41 (95% CI −0.53, −0.28). These results show statistical significance with a substantial heterogeneity ($I^2 = 73.5%$, p < 0.001) (Fig. 3). For studies with a follow-up period of 1–4 months, the heterogeneity was substantial ($F = 72.3%$, p = 0.003) and the mean difference was −0.51 kg (95% CI −0.68, −0.34), studies with 5–12 months had a considerable heterogeneity ($F = 76.8%$, p < 0.001) and mean difference −0.32 kg (95% CI −0.58, −0.07), whereas when the follow-up was >12 months, there was a substantial heterogeneity ($F = 70.3%$, p < 0.018) and mean difference −0.20 kg (95% CI −0.49, 0.10) (Fig. 4). We performed a meta-analysis of high-quality studies with an overall weight loss control group mean difference of −0.16 (95% CI −0.39, 0.09) and a considerable heterogeneity ($F = 74%$, p < 0.000) (Fig. 5). As the exploration of heterogeneity leads to more meaningful, high-value conclusions, we also performed a meta-analysis comparing subgroups by type of care protocols in control group. Among studies including control group in waiting lists and combining standard care, advice and material, no heterogeneity was found ($F = 0%$, p = 0.589) and ($F = 0%$, p = 0.438), and the mean difference was −0.84 kg (95% CI −2.47, 0.80) and −0.65 kg (95% CI −1.03, −0.27), respectively. In studies with standard care and material, the heterogeneity was substantial ($F = 68.2%$, p = 0.004) and the mean difference was −0.47 kg (95% CI −0.65, −0.28). Finally, in the studies where control group participants received standard care, or standard care and advice, we found a considerable heterogeneity ($F = 85.4%$, p = 0.000) and ($F = 85.8%$, p = 0.001) with a mean difference of −0.48 kg (95% CI −0.76, −0.20) and 0.00 kg (−0.30, 0.30) (Fig. 6).

| References       | Country     | Population randomized (N) and follow-up period | Patients’ characteristics | Type of intervention | Lost weight objective | Diet advice | Physical activity advice | Type of intervention Length and duration of interventions | Type of care protocols in CG | Personnel conducting intervention | Weight loss in CG Mean difference (SD) and 95% CI |
|------------------|-------------|-----------------------------------------------|---------------------------|----------------------|----------------------|-------------|-------------------------|----------------------------------------------------------|-------------------------------|----------------------------------------|------------------------------------------|
| Röhling46         | Germany     | N = 30 1 year                                 | Age > 18 BMI ≥ 25          | LWO: Not specified DA: Low-carbohydrate nutrition and meal replacement therapy PAA: To increase TOI: Group-based L-DI: During 3 months intervention: 7 theoretical sessions and two practical modules of 90 each, and 4 telephone calls (20–30 each) monthly | Waitlisted to receive the programme after post-test data collection | Nutritionists, exercise scientists, biologists, physicians and psychologists | PAA: TOI Protocol: 6 months |
| Jordi Salas Salvadó43 | Spain      | N = 626 12 months                            | Age: 55–75 Patients without CVD, overweight/obese (BMI > 27 and < 40) and with MetS | LWO: ≤ 5–10% reduction DA: Mediterranean diet PAA: To increase TOI: Individual and group-based L-DI: During 12 months: group sessions and telephone calls once per month | Standard care Advice about Mediterranean diet monthly without specific advice for increasing PA. Group sessions and telephone calls every 6 months | Doctors, dietitians and nurses | PAA: TOI Protocol: 6 months |
| Pablos48          | Spain       | N = 97 8 months                              | Age: 20–70 Adults with BMI > 25, no regular PA living in a low median household income census tract | LWO: Not specified DA: Personalized diet advice PAA: To increase TOI: Individual and group-based L-DI: 8-month intervention: 3 sessions/week of PA (140–180’) and 1 session/week of nutritional or psychological support (60’) | Waitlisted to receive the programme after post-test data collection | Doctors, nutritionists, nurses, psychologists and trainers | L-DI: 8-month Protocol: 6 months

Table 1. Characteristics of studies included in the review. BMI Body mass index; CG Control group; CVD Cardiovascular disease; MetS Metabolic syndrome; PA Physical activity; OSAHS Obstructive sleep apnoea hypopnoea syndrome; SD Standard deviation; LWO Lost weight objective; DA Diet advice; PAA Physical activity advice; TOI Type of intervention; L-DI Length and duration of interventions.
Discussion

Our meta-analysis of over four thousand participants combined showed that control groups in obesity research lost weight overall, confirming that it is safe and beneficial to participate in trials even if the allocation is not to the intervention arm.

To our knowledge, this is the first systematic review and meta-analysis focusing on control group outcomes in lifestyle intervention studies. Our findings confirm the hypothesis of health improvement of control participants, in contrast to the results on overall weight changes in a meta-regression study on behavioural weight loss interventions\(^1\). Our search was unrestricted, without limitations regarding language or dataset inception, to capture the highest possible number of relevant studies. There was reviewer agreement in the search, selection and quality assessment of studies adding to reliability of our work. However, our main finding was within the limitations placed by heterogeneity. This is an expected, possibly unavoidable, limitation when addressing lifestyle interventions\(^4\). In our review there are various possible sources of heterogeneity. Standard healthcare in control groups may vary between participants depending on the health systems in the countries where trials are carried out. We also found a diversity of approaches in handling control group engagement, e.g., providing health educational contents with a variable frequency, within the trials included, which may have different effect.

**Figure 2.** Quality assessment of the studies included in the review using Jadad scale.
With a considerable sample size, we could precisely estimate the control group weight loss. The reporting of some of the studies did not facilitate the analysis of the control group, as findings were mainly reported for intergroup differences. However, in the three mentioned articles not providing required parameters for meta-analysis, we were able to estimate them from the available data. Despite the issues arising from data reporting quality, our overall result was statistically significant.

How did the control group come to benefit? The observed benefits may be due to a trial effect, which increases adherence to care protocols and encourages interaction between patients and professionals. Additionally, the Hawthorne effect could improve control group outcome through modification of the behaviour of research participants just because they are observed in the course of a trial. The observed fact that the control groups benefit is generally in line with the view that participating in RCTs is good for participants. This finding is particularly important as the prevalent overweight and obesity rates are high. For example, in Spanish population aged 55–64 years the prevalence of overweight and obesity reaches 44% and 22% respectively. As the mean age of the control group participants in Spain was 60 years, trial participation could be thought of as a strategy for weight control. The same theme is repeated for the USA, where north American studies showed a mean age of 51 years and the prevalence of overweight and obesity in the over 50s is 70%.

Despite the magnitude of the effect in control group participants is not large, the fact that they experienced a weight loss inverses population trends of progressive gain during adult life. Beyond the individual benefit, this weight loss may have a high impact of the health outcomes when extended to general population, in terms of improvement of health status and reduction of burden for health systems. Health services should also consider implementing lifestyle intervention trials as part of programs for people with overweight and obesity.

Lifestyle research has shown health benefits of intervention compared to control in terms of adiposity and cardiovascular risk decrease. Our findings also show a benefit in the outcome of the control groups. Future research should examine if the benefits gained by participation in the control groups can be maintained over time as a healthy weight loss has a tendency to be gradually regained. These benefits should be used to encourage participation in future obesity research to generate the timely evidence for practice and policy.

### Table 2: ES (95% CI) of weight loss outcome in control group participants in lifestyle randomized controlled trials.

| Study ID | ES (95% CI) | Weight |
|----------|-------------|---------|
| Greaves, 2015 | -2.04 (-3.96, 0.12) | 0.39 |
| Lin, 2015 | -0.20 (-1.40, 1.00) | 1.13 |
| Weinhold, 2015 | -0.40 (-0.59, -0.21) | 45.24 |
| E.-G. Oh, 2008 | -2.00 (-8.59, 4.59) | 0.04 |
| Alghamdi, 2017 | -2.80 (-3.96, -1.64) | 1.21 |
| Blackford, 2016 | 1.10 (-2.29, 4.49) | 0.14 |
| Fernández-Ruiz, 2018 | -0.20 (-4.18, 3.78) | 0.10 |
| Bo, 2007 | 1.63 (0.83, 2.42) | 2.58 |
| Duijzer, 2017 | -0.40 (-1.06, 0.26) | 3.75 |
| Christensen, 2011 | 0.68 (-0.02, 1.38) | 3.33 |
| Kandula, 2015 | -0.20 (-1.14, 0.78) | 1.77 |
| Thiabrero, 2017 | -0.70 (-1.20, -0.20) | 6.53 |
| Cai, 2019 | -0.03 (-0.37, 0.31) | 14.13 |
| Nanri, 2012 | -0.30 (-2.40, 1.80) | 0.37 |
| Maruyama, 2010 | -0.80 (-1.50, -0.10) | 3.33 |
| Share, 2015 | -3.60 (-13.20, 6.00) | 0.02 |
| Moss, 2014 | 0.20 (-8.11, 8.51) | 0.02 |
| Puhkala, 2015 | -2.50 (-4.02, -0.98) | 0.71 |
| Anderson, 2021 | -1.20 (-1.80, -0.60) | 4.54 |
| Röling, 2020 | -1.40 (-3.30, 0.60) | 0.43 |
| Jordi Salas-Salvadó, 2019 | -0.70 (-1.10, -0.30) | 10.21 |
| Pablos, 2017 | -0.13 (-8.46, 8.20) | 0.02 |
| Overall (I-squared = 73.5%, p = 0.000) | -0.41 (-0.53, -0.28) | 100.00 |

ES: Effect size, mean difference from baseline to post-participation.

Figure 3. Meta-analysis of weight loss outcome in control group participants in lifestyle randomized controlled trials.
Conclusions

Our systematic review showed that participation in control groups of RCTs of lifestyle interventions had a benefit in terms of weight loss in meta-analysis with heterogeneity. These results should be used to interpret the benefits observed with respect to intervention effect in trials. That control groups accrue benefits should be included in patient information sheets to encourage participation in future trials among patients with overweight or obesity.

Figure 4. Meta-analysis of weight loss outcome in control group participants stratified by duration of follow-up in lifestyle randomized controlled trials.

ES: Effect size, mean difference from baseline to post-participation.
Figure 5. Meta-analyses of weight loss outcome in control group participants stratified by high-quality lifestyle randomized controlled trials.

ES: Effect size, mean difference from baseline to post-participation.
ES: Effect size, mean difference from baseline to post-participation.

Figure 6. Meta-analysis of weight loss outcome stratified by type of care protocols in control group participants in lifestyle randomized controlled trials.

Data availability
All data generated or analysed during this study are included in this published article (Appendix 2–4).

Received: 10 February 2022; Accepted: 29 June 2022
Published online: 18 July 2022

References
1. Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat. Rev. Endocrinol. 15, 288–298. https://doi.org/10.1038/s41574-019-0176-8 (2019).
2. The Lancet, G., & Hepatology. Obesity: another ongoing pandemic. Lancet Gastroenterol. Hepatol. 6, 411. https://doi.org/10.1016/S2468-1253(21)00143-6 (2021).
3. Zhao, N., Tao, K., Wang, G. & Xia, Z. Global obesity research trends during 1999 to 2017: A bibliometric analysis. Medicine 98, e14132. https://doi.org/10.1097/md.0000000000014132 (2019).
4. Tremmel, M., Gerddham, U. G., Nilsson, P. M., & Saha, S. Economic burden of obesity: A systematic literature review. Int. J. Environ. Res. Public Health. https://doi.org/10.3390/ijerph140100435 (2017).
5. Lindström, D., Sundberg-Petersson, I., Adami, J. & Tönnesen, H. Disappointment and drop-out rate after being allocated to control group in a smoking cessation trial. Contemp. Clin. Trials 31, 22–26. https://doi.org/10.1016/j.cct.2009.09.003 (2010).
6. Groeneveld, I. F., Proper, K. I., van der Beek, A. J., Hildebrandt, V. H. & van Mechelen, W. Factors associated with non-participation and drop-out in a lifestyle intervention for workers with an elevated risk of cardiovascular disease. Int. J. Behav. Nutr. Phys. Act 6, 80. https://doi.org/10.1186/1479-5868-6-80 (2009).
7. Lemstra, M., Bird, Y., Nwankwo, C., Rogers, M. & Moraros, J. Weight loss intervention adherence and factors promoting adherence: A meta-analysis. Patient Prefer. Adherence 10, 1547–1559. https://doi.org/10.2147/ppa.s103649 (2016).
8. Mutsaerts, M. A., Kuchenbecker, W. K., Mol, B. W., Land, J. A. & Hoek, A. Dropout is a problem in lifestyle intervention programs for overweight and obese infertile women: A systematic review. Hum. Reprod. 28, 979–986. https://doi.org/10.1093/humrep/det026 (2013).

9. Eaglehouse, Y. L. et al. Impact of a community-based lifestyle intervention program on health-related quality of life. Qual. Life Res. 25, 1903–1912. https://doi.org/10.1007/s11136-016-1240-7 (2016).

10. Vist, G. E., Bryant, D., Somerville, L., Birmingham, T. & Oxman, A. D. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst. Rev. 2008, MR000009. https://doi.org/10.1002/14651858.MR000009.pub4 (2008).

11. Nijjar, S. K. et al. Participation in clinical trials improves outcomes in women’s health: A systematic review and meta-analysis. BJOG 124, 863–871. https://doi.org/10.1111/1465-0664.12528 (2017).

12. Clarke, M. & Loudon, K. Effects on patients of their healthcare practitioner’s or institution’s participation in clinical trials: A systematic review. Trials 12, 16. https://doi.org/10.1186/1745-6215-12-16 (2011).

13. Braunholtz, D. A., Edwards, S. J. & Lilford, R. J. Are randomized clinical trials good for us (in the short term)? Evidence for a “trial effect”. J. Clin. Epidemiol. 54, 217–224. https://doi.org/10.1016/s0895-4356(00)00305-x (2001).

14. Cross, C. P., Krumholz, H. M., Van Wye, G., Emanuel, E. J. & Wendler, D. Does random treatment assignment cause harm to research participants? PLoS Med. 3, e188. https://doi.org/10.1371/journal.pmed.0030188 (2006).

15. Fernandes, N. et al. Outcomes for patients with the same disease treated inside and outside of randomized trials: A systematic review and meta-analysis. CMAJ 186, E596–E609. https://doi.org/10.1503/cmaj.131693 (2014).

16. Waters, L., George, A. S., Chey, T. & Bauman, A. Weight change in control group participants in behavioural weight loss interventions: A systematic review and meta-regression study. BMC Med. Res. Methodol. https://doi.org/10.1186/1471-2288-12-120 (2012).

17. Byrd-Bredbenner, C. et al. Systematic review of control groups in nutrition education intervention research. Int. J. Behav. Nutr. Phys. Act 14, 91. https://doi.org/10.1186/1479-5868-12-91 (2017).

18. Glanz, K., Sorensen, G. & Farmer, A. The health impact of worksite nutrition and cholesterol intervention programs. Am. J. Health Promot. 10, 453–470. https://doi.org/10.4278/1097-1711-10.6.453 (1996).

19. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008–2012. https://doi.org/10.1001/jama.283.15.2008 (2000).

20. Jadad, A. R. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin. Trials 17, 1–12. https://doi.org/10.1016/S0197-2456(95)00134-4 (1996).

21. Moss, J. et al. Effects of a pragmatic lifestyle intervention for reducing body mass in obese adults with obstructive sleep apnoea: A randomised controlled trial. BioMed Res. Int. https://doi.org/10.1155/2014/102164 (2014).

22. Oh, E.-G. et al. A randomized controlled trial of therapeutic lifestyle modification in rural women with metabolic syndrome: A pilot study. J. Metab. Clin. Exp. 57, 255–261. https://doi.org/10.1016/j.mce.2009.09.009 (2009).

23. Share, B. L. et al. Effects of a multi-disciplinary lifestyle intervention on cardiometabolic risk factors in young women with abdominal obesity: A randomised controlled trial. PLoS ONE. https://doi.org/10.1371/journal.pone.0130270 (2015).

24. Morris, S. B. & DeShon, R. P. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol. Methods 7, 105–123. https://doi.org/10.1186/1476-9238-7-1.105 (2002).

25. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008–2012. https://doi.org/10.1001/jama.283.15.2008 (2000).

26. McKenzie, J. E. et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. Prev. Med. 51, 11–17. https://doi.org/10.1016/j.ypmed.2010.04.008 (2010).

27. Pulkala, J. et al. Lifestyle counseling to reduce body weight and cardiometabolic risk factors among truck and bus drivers—a randomized controlled trial. Scand. J. Work Environ. Health 41, 54–64. https://doi.org/10.5271/sjweh.3463 (2015).

28. Weinhold, K. R. et al. A randomized controlled trial translating the diabetes prevention program to a university worksite, Ohio, 2012–2014. Preventing Chronic Disease. https://doi.org/10.5888/pcd12.150301 (2015).

29. Duiziger, G. et al. Effect and maintenance of the SLIMMER diabetes prevention lifestyle intervention in Dutch primary healthcare: A randomised controlled trial. Nutr. Diabetes. https://doi.org/10.1186/s1329-017-0121-7 (2017).

30. Fernández-Ruiz, V. E. et al. Effectiveness of the 12 AO 2 interdisciplinary programme led by nurses on metabolic syndrome and cardiovascular risk: a randomized, controlled trial. Int. Med. Res. 46, 2202–2218. https://doi.org/10.1177/0300060518757604 (2018).

31. Bo, S. et al. Effectiveness of lifestyle intervention on metabolic syndrome. A randomized controlled trial. J. Gen. Intern. Med. 22, 1697–1703. https://doi.org/10.1007/s11606-007-0399-6 (2007).

32. Anderson, A. S. et al. A novel approach to increasing community capacity for weight management a volunteer-delivered programme (ActWELL) initiated within breast screening clinics: A randomised controlled trial. Int. J. Behav. Nutr. Phys. Activity. https://doi.org/10.1186/s12966-021-01099-7 (2021).

33. Cai, H. et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial. BMC Gastroenterol. https://doi.org/10.1186/s12876-019-1312-8 (2019).

34. Graves, C. et al. Waste the waist: A pilot randomised controlled intervention to support lifestyle change in people with high cardiovascular risk. Int. J. Behav. Nutr. Phys. Activity. doi:https://doi.org/10.1186/s12966-014-0159-z (2015).

35. Lin, M. et al. Tailored, interactive text messages for enhancing weight loss among African American Adults: The TRIMM randomized controlled trial. Am. J. Med. 128, 896–904. https://doi.org/10.1016/j.amjmed.2015.03.013 (2015).

36. Alghamdi, R. R. Q. A randomized controlled trial of a 12-week lifestyle intervention program at a primary care obesity clinic for adults in western Saudi Arabia. Saudi Med. J. 38, 837–845. https://doi.org/10.15573/smj.2017.8.0553 (2017).

37. Kandula, N. R. et al. Translating a heart disease lifestyle intervention into the community: the South Asian Heart Lifestyle Intervention (SAHELI) study; A randomized control trial. BMC Public Health 15, 1064. https://doi.org/10.1186/s12889-015-2401-2 (2015).

38. Salas-Salvadó, J. et al. Effect of a lifestyle intervention program with energy-restricted Mediterranean Diet and exercise on weight loss and cardiovascular risk factors: One-year results of the PREDIMED-Plus Trial. Diabetes Care 42, 777–788. https://doi.org/10.2337/dc18-0836 (2019).
44. Blackford, K. et al. Home-based lifestyle intervention for rural adults improves metabolic syndrome parameters and cardiovascular risk factors: A randomised controlled trial. *Prev. Med.* **89**, 15–22. https://doi.org/10.1016/j.ympmed.2016.05.012 (2016).

45. Röhling, M. et al. Weight reduction by the low-insulin-method—a randomized controlled trial. *Nutrients* **12**, 1–17. https://doi.org/10.3390/nu12103004 (2020).

46. Pablos, A. et al. Effects of a lifestyle intervention program for treating obesity in lower socioeconomic status adults: a randomized controlled trial. *Gazzetta Medica Italiana Archivio Per Le Scienze Mediche* **176**, 467–477. https://doi.org/10.23736/s0393-3660.17.03407-6 (2017).

47. Cai, R. et al. Effect of community-based lifestyle interventions on weight loss and cardiometabolic risk factors in obese elderly in China: A randomised controlled trial. *Exp. Gerontol.* https://doi.org/10.1016/j.exger.2019.110749 (2019).

48. Malakou, E. et al. The combined effect of promoting the mediterranean diet and physical activity on metabolic risk factors in adults: A systematic review and meta-analysis of randomised controlled trials. *Nutrients*. https://doi.org/10.3390/nu10111577 (2018).

49. Montesi, L. et al. Long-term weight loss maintenance for obesity: a multidisciplinary approach. *Diabetes Metab. Syndr. Obes.* **9**, 37–46. https://doi.org/10.2147/dmso.S9836 (2016).

50. McCambridge, J., Witton, J. & Elbourne, D. R. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. *J. Clin. Epidemiol.* **67**, 267–277. https://doi.org/10.1016/j.jclinepi.2013.08.015 (2014).

51. Índice de masa corporal población adulta según sexo y grupo de edad. Población de 18 y más años, <https://www.ine.es/jaxi/Datos.htm?path=/t15/p419/p2017/p06/l0/&file=01001.px#tabs-tabla> (2021).

52. Roser, H. R. & Max. Obesity. <https://ourworldindata.org/obesity> (2021).

53. Alvarez León, E. E. & Vioque, J. [Weight gain along adult life], *Med Clin (Barc)* **117**, 172–174. https://doi.org/10.1016/s0025-7753(17)32052-0 (2001).

54. Rose, G. Sick individuals and sick populations. *Int. J. Epidemiol.* **14**, 32–38. https://doi.org/10.1093/ije/14.1.32 (1985).

55. Rose, G. Strategy of prevention: Lessons from cardiovascular disease. *Br. Med. J. (Clin. Res. Ed.)* **282**, 1847–1851. https://doi.org/10.1136/bmj.282.6279.1847 (1981).

56. van Namen, M., Prendergast, L. & Peiris, C. Supervised lifestyle intervention for people with metabolic syndrome improves outcomes and reduces individual risk factors of metabolic syndrome: A systematic review and meta-analysis. *Metabolism* **101**, 153988. https://doi.org/10.1016/j.metabol.2019.153988 (2019).

57. Cano-Ibáñez, N. et al. Diet quality and nutrient density in subjects with metabolic syndrome: Influence of socioeconomic status and lifestyle factors. A cross-sectional assessment in the PREDIEM-Plus study. *Clin. Nutr.* **39**, 1161–1173. https://doi.org/10.1016/j.clnu.2019.04.032 (2020).

58. Cano-Ibáñez, N. et al. Effect of changes in adherence to Mediterranean diet on nutrient density after 1-year of follow-up: Results from the PREIDIM-Plus Study. *Eur. J. Nutr.* **59**, 2395–2409. https://doi.org/10.1007/s00394-019-02087-1 (2020).

59. Christian, J. G., Tsai, A. G. & Bessesen, D. H. Interpreting weight losses from lifestyle modification trials: using categorical data. *Int. J. Obes. (Lond.)* **34**, 207–209. https://doi.org/10.1038/ijo.2009.213 (2010).

Acknowledgements
The first author would like to acknowledge support by the CIBER Epidemiología y Salud Pública (CIBERESP/CB06/02/1014). Professor Khan is a Distinguished Investigator at the University of Granada funded by the Beatriz Galindo (senior modality) program of the Spanish Ministry of Education.

Author contributions
All authors contributed in the conception of the research question and designed the study. A.B.H. did the literature search, study selection and data extraction, and double checked by P.M.G. N.C.I., A.B., K.S.K. and A.B.C. did the statistical analysis. The figures, tables and appendices were designed by A.B.H. All authors contributed to the drafts and final version of the manuscript.

Funding
This research has received funding from the Ministry of Science and Innovation, Instituto de Salud Carlos III, FEDER co-funding from European Union (P120/01532 project), and the Centro de Investigación Biomédica en Red-Epidemiología y Salud Pública (CIBERESP/CB06/02/1014).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-15770-x.

Correspondence and requests for materials should be addressed to P.M.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022